|
Ruiz-Lorente I, Gimeno L, Lopez-Abad A, Lopez Cubillana P, Fernandez Aparicio T, Asensio Egea LJ, Moreno Aviles J, Donate Iniguez G, Guzman Martinez-Valls PL, Server G, Ferri B, Campillo JA, Martinez-Sanchez MV, Minguela A. Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with M. bovis BCG or Other Therapies. Biomedicines. 2025 Jan 10;13(1):156. doi: 10.3390/biomedicines13010156. PubMed PMID: 39857739; PubMed Central PMCID: PMC11760850.
AÑO: 2025; IF: 3.9
|
39857739
|
Pons-Fuster E, Martinez-Rodriguez R, Gimeno-Arias L, Alcaraz MJ, Moreno M, Gomez JM, Pelaez A, Garcia E, Tomas C, Munoz A, Martinez-Sanchez MV, Ruiz-Lorente I, Ceballos D, Minguela A, Bernal E. HLA-A*03 may confer protection against long COVID through an enhanced immune response. Infect Dis Now. 2025 Mar 17:105057. doi: 10.1016/j.idnow.2025.105057. Online ahead of print. PubMed PMID: 40107360.
AÑO: 2025; IF: 2.2
|
|
Ramos Elbal E, Fuster JL, Campillo JA, Galera AM, Cortes MB, Llinares ME, Jimenez I, Plaza M, Martinez Banaclocha H, Galian JA, Blanquer Blanquer M, Martinez Sanchez MV, Muro M, Minguela A. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia. Clin Transl Oncol. 2024 Jan;26(1):278-287. doi: 10.1007/s12094-023-03251-0. Epub 2023 Jun 27. PubMed PMID: 37368200.
AÑO: 2024; IF: 2.5
|
|
Ruiz-Lorente I, Gimeno L, Lopez-Abad A, Lopez Cubillana P, Fernandez Aparicio T, Asensio Egea LJ, Moreno Aviles J, Donate Iniguez G, Guzman Martinez-Valls PL, Server G, Escudero-Bregante JF, Ferri B, Campillo JA, Pons-Fuster E, Martinez Hernandez MD, Martinez-Sanchez MV, Ceballos D, Minguela A. Exploring the Immunoresponse in Bladder Cancer Immunotherapy. Cells. 2024 Nov 22;13(23):1937. doi: 10.3390/cells13231937. PubMed PMID: 39682686; PubMed Central PMCID: PMC11640729.
AÑO: 2024; IF: 5.2
|
|
Ramos Elbal E, Fuster JL, Campillo JA, Galera AM, Cortes MB, Llinares ME, Jimenez I, Plaza M, Banaclocha HM, Galian JA, Blanquer Blanquer M, Martinez Sanchez MV, Muro M, Minguela A. Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia. Clin Transl Oncol. 2023 May;25(5):1446-1454. doi: 10.1007/s12094-022-03042-z. Epub 2023 Jan 4. PubMed PMID: 36598635.
AÑO: 2023; IF: 2.8
|